Retraction : "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial"
© 2024 Wiley Periodicals LLC..
Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial," by Salimian J, Ahmadi A, Amani J, et al. J Med Virol. 2022;95:e28097. The above article, published online on August 27, 2022 in Wiley Online Library (https://onlinelibrary.wiley.com/doi/10.1002/jmv.28097) has been retracted by agreement between the journal's Editor in Chief, Shou-Jiang (SJ) Gao, and Wiley Periodicals LLC. The retraction has been agreed due to concerns raised by third parties regarding issues with the data presented in the article.1 Several inconsistencies concerning the information provided about the analyzed subjects were additionally identified. Furthermore, the authors failed to disclose the presence of potential conflicts of interest that may have affected the interpretation of the results presented. Accordingly, the editors consider the conclusions of this manuscript to be invalid. The authors have been informed of the decision to retract but did not agree with it. REFERENCE 1. Forthal DN. Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2. J Med Virol. 2023;95:e28731. doi:10.1002/jmv.28731.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Journal of medical virology - 96(2024), 3 vom: 02. März, Seite e29509 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 02.03.2024 published: Print RetractionOf: J Med Virol. 2023 Feb;95(2):. - PMID 36029105 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/jmv.29509 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369200829 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369200829 | ||
| 003 | DE-627 | ||
| 005 | 20240302233030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.29509 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM369200829 | ||
| 035 | |a (NLM)38430205 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Retraction |b "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial" |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a RetractionOf: J Med Virol. 2023 Feb;95(2):. - PMID 36029105 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial," by Salimian J, Ahmadi A, Amani J, et al. J Med Virol. 2022;95:e28097. The above article, published online on August 27, 2022 in Wiley Online Library (https://onlinelibrary.wiley.com/doi/10.1002/jmv.28097) has been retracted by agreement between the journal's Editor in Chief, Shou-Jiang (SJ) Gao, and Wiley Periodicals LLC. The retraction has been agreed due to concerns raised by third parties regarding issues with the data presented in the article.1 Several inconsistencies concerning the information provided about the analyzed subjects were additionally identified. Furthermore, the authors failed to disclose the presence of potential conflicts of interest that may have affected the interpretation of the results presented. Accordingly, the editors consider the conclusions of this manuscript to be invalid. The authors have been informed of the decision to retract but did not agree with it. REFERENCE 1. Forthal DN. Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2. J Med Virol. 2023;95:e28731. doi:10.1002/jmv.28731 | ||
| 650 | 4 | |a Retraction of Publication | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 96(2024), 3 vom: 02. März, Seite e29509 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2024 |g number:3 |g day:02 |g month:03 |g pages:e29509 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29509 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2024 |e 3 |b 02 |c 03 |h e29509 | ||